Acta Neurochirurgica

, Volume 161, Issue 3, pp 597–600 | Cite as

Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab

  • Atsushi OgataEmail author
  • Kazuhiko Oho
  • Noriaki Matsumoto
  • Jun Masuoka
  • Kohei Inoue
  • Motofumi Koguchi
  • Fumitaka Yoshioka
  • Tatsuya Abe
Case Report - Vascular Neurosurgery - Ischemia
Part of the following topical collections:
  1. Vascular Neurosurgery - Ischemia


Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduce low-density lipoprotein cholesterol levels and improve outcomes of myocardial infarction and stroke. However, the effects of PCSK9 inhibitors on carotid plaques remain unclear. We describe three patients treated with PCSK9 inhibitor alirocumab for progressive carotid stenosis despite lipid-lowering statin therapy. All three patients had vulnerable plaques on magnetic resonance (MR) plaque imaging. After alirocumab treatment initiation, no patients suffered stroke or adverse events, and the stabilization of the carotid plaques was observed on MR plaque imaging.


Carotid artery Progressive Alirocumab Proprotein convertase subtilisin/kexin type 9 inhibitor Magnetic resonance imaging 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Informed consent

Informed consent was obtained from all patients in this case report.


  1. 1.
    Gupta A, Baradaran H, Schweitzer AD, Kamel H, Pandya A, Delgado D, Dunning A, Mushlin AI, Sanelli PC (2013) Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke 44:3071–3077. CrossRefGoogle Scholar
  2. 2.
    Kakkos SK, Nicolaides AN, Charalambous I, Thomas D, Giannopoulos A, Naylor AR, Geroulakos G, Abbott AL (2014) Predictors and clinical significance of progression or regression of asymptomatic carotid stenosis. J Vasc Surg 59:956–967.e951. CrossRefPubMedGoogle Scholar
  3. 3.
    Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. Jama 316:2373–2384. CrossRefPubMedGoogle Scholar
  4. 4.
    Saam T, Ferguson MS, Yarnykh VL, Takaya N, Xu D, Polissar NL, Hatsukami TS, Yuan C (2005) Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler Thromb Vasc Biol 25:234–239. CrossRefPubMedGoogle Scholar
  5. 5.
    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722. CrossRefPubMedGoogle Scholar
  6. 6.
    Shapiro MD, Tavori H, Fazio S (2018) PCSK9: from basic science discoveries to clinical trials. Circ Res 122:1420–1438. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sun J, Zhao XQ, Balu N, Neradilek MB, Isquith DA, Yamada K, Canton G, Crouse JR 3rd, Anderson TJ, Huston J 3rd, O’Brien K, Hippe DS, Polissar NL, Yuan C, Hatsukami TS (2017) Carotid plaque lipid content and fibrous cap status predict systemic CV outcomes: the MRI substudy in AIM-HIGH. JACC Cardiovasc Imaging 10:241–249. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Watanabe Y, Nagayama M, Sakata A, Okumura A, Amoh Y, Ishimori T, Nakashita S, Dodo Y (2014) Evaluation of fibrous cap rupture of atherosclerotic carotid plaque with thin-slice source images of time-of-flight MR angiography. Ann Vasc Dis 7:127–133. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Xie W, Liu J, Wang W, Wang M, Qi Y, Zhao F, Sun J, Liu J, Li Y, Zhao D (2016) Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study. Int J Cardiol 215:293–298. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, Faculty of MedicineSaga UniversitySagaJapan
  2. 2.Department of NeurosurgeryYanagawa HospitalYanagawaJapan
  3. 3.Department of Internal MedicineYanagawa HospitalYanagawaJapan
  4. 4.Department of CardiologyYanagawa HospitalYanagawaJapan

Personalised recommendations